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Abstract 
Many patients with multiple myeloma (MM) are elderly (aged >65 years) or unfit, and therefore 
ineligible for stem-cell transplantation. The novel agents thalidomide, bortezomib, and lenalidomide 
have shown improved outcomes in these patients. This article discusses the role of continuous 
therapy in improving patient outcomes and how novel agents with better tolerability profiles could 
lead to a change in the treatment paradigm. According to the proposed concept, treatment of 
transplant-ineligible patients with MM should include achievement of high-quality responses with 
effective induction combination regimens, as well as maintenance of the response with long-term 
therapy for optimal sustained efficacy. 
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Multiple myeloma (MM) is a disease that primarily occurs in older patients. Statistics from the 
USA show a rise in the incidence of MM from 2.2 per 100,000 people aged <65 years to 30.6 per 
100,000 people aged ≥65 years [1]. A survival trend analysis of patients diagnosed with MM from 
1997 to 2006 showed that, during this time period, median survival increased from 29.9 months to 
44.8 months [2]. Improvements in patient outcomes are largely attributed to better supportive care, 
increased use of high-dose therapy (HDT) and autologous stem-cell transplantation (ASCT) in 
eligible patients, and the introduction of the novel agents thalidomide, bortezomib, and 
lenalidomide 2 and 3. 
However, these survival benefits, which were predominantly observed in younger patients, have not 
been as clear in older patients 2, 3 and 4. A study of survival in unselected patients with MM 
diagnosed between 1950 and 2005 observed a doubling of median overall survival (OS) in patients 
aged ≤65 years during the period 1995–2005, but no significant improvement in patients aged >65 
years at diagnosis [3]. Among patients with newly diagnosed MM (NDMM), median survival rose 
from 33 months to 60 months for those aged <65 years; however, for older patients median survival 
increased only marginally from 26 to 32 months [2]. The most recent statistics from the USA 
indicate that the 5-year relative survival for MM patients aged <65 years is 57%; however, this rate 
falls to 29% for those aged ≥65 years, and to 22% for those aged ≥75 years [1]. Others have 
reported that age is associated with higher International Staging System stage, which is a significant 
risk factor for early mortality in patients with MM [5]. 
For the purpose of making treatment decisions, patients with symptomatic NDMM are generally 
categorized as transplantation-eligible and -ineligible. Criteria that have been used to indicate 
transplantation ineligibility include age >65 years or >70 years, physical fitness/health, serum 
creatinine level >2.5 mg/dl, Eastern Cooperative Oncology Group (ECOG) performance status 
score of 3 or 4, major organ (liver, heart, lung, or kidney) dysfunction, history of thrombosis, and 
the presence of other serious comorbidities 6 and 7. The International Myeloma Working Group 
(IMWG) guidelines [6] note that in most countries, with the exception of the USA, patients aged 
>65 years are not considered for transplantation. Furthermore, no randomized trial has shown a 
survival advantage for patients aged >65 receiving ASCT. The National Comprehensive Cancer 
Network (NCCN) guidelines for MM do not specify an age limit for ASCT [7]; however, questions 
remain regarding the impact of this procedure and the related serious toxicities on quality of life 
8 and 9. 
For patients for whom ASCT is not an option, the treatment goal is to control disease progression 
for the purpose of extending OS while maintaining a good quality of life 10 and 11. Historically, 
patients ineligible for HDT-ASCT were treated with alkylating-based regimens, mainly using 
melphalan plus prednisone (MP), cyclophosphamide, or dexamethasone resulting in overall 
response rates (ORR) of 40–50%, complete response (CR) rates of <5%, and a median OS of 3 
years 9 and 12. 
More recently, the introduction of regimens containing thalidomide, bortezomib, and lenalidomide 
has been associated with improved outcomes in patients with NDMM or relapsed and refractory 
MM (RRMM) [13]. However, the ideal duration of therapy has not yet been defined. Most 
physicians treat patients for 1–2 years, after which treatment is stopped, placing the patient at risk of 
relapse usually within 1 year following treatment cessation [14]. It has been proposed that 
continuous therapy can suppress minimal residual disease (MRD) and thus extend the remission 
duration [15]. This article discusses the role of continuous therapy in improving outcomes in 
transplantation-ineligible patients and how the availability of novel agents, with better tolerability 
profiles, could allow for a change in the management of these patients. 
2. Novel agents as induction therapy in transplant-ineligible patients 
2.1. Thalidomide 
The addition of thalidomide to the conventional MP regimen (MPT) has been studied in six phase 
III randomized controlled trials in older patients with NDMM, and a meta-analysis of these trials, 
including 1685 patients, was recently reported [16]. The meta-analysis included studies with and 
without thalidomide maintenance as part of the MPT treatment arm. Across studies, MPT was 
associated with a significantly longer progression-free survival (PFS; 20.3 months vs 14.9 months 
with MP; hazard ratio [HR] = 0.68; p < 0.0001). Importantly, MPT was associated with a 
significant improvement in OS, extending OS by 6.6 months to 39.3 months, and reducing the risk 
of death by 17% compared with MP (p = 0.004). However, the improved efficacy of MPT came at 
the cost of increased toxicity, including a 2.4-fold increased risk of peripheral neuropathy (p = 0.02) 
and a 6.6-fold increased risk of deep-vein thrombosis (p < 0.001) versus MP, as shown in another 
meta-analysis including five of the six MPT trials [17]. Furthermore, individual studies show that 
MPT is also associated with an increased rate of treatment discontinuation compared with MP (22–
42% vs 6–13%, respectively) 18, 19 and 20. Based on this high level of clinical evidence, the MPT 
regimen is established as one of the available standards of care for patients aged >65 years [6]. 
2.2. Bortezomib 
In the original VISTA randomized phase III trial after 16.3 months follow-up, the addition of 
bortezomib (V) to the MP regimen (VMP) improved median time-to-progression (TTP), and 
significantly improved survival by 39% (p = 0.008) [21]. An updated analysis after a median 
follow-up period of 36.7 months, showed that the median OS was higher with VMP than with MP 
(not reached vs 43.1 months, respectively; HR = 0.65; p < 0.001) [22]. Peripheral neuropathy (any 
grade: 44% vs 5%), gastrointestinal adverse events (AEs; grade ≥ 3: 19% vs 5%), and herpes zoster 
infection (any grade: 13% vs 4%) were reported more frequently among patients treated with VMP 
compared with those treated with MP. VMP is given for a total of nine treatment cycles of 6 weeks. 
VMP is another standard of care in elderly patients [6]. 
2.3. Lenalidomide 
The ECOG E4A03 randomized open-label non-inferiority study compared lenalidomide plus high-
dose dexamethasone (40 mg on days 1–4, 9–12, and 17–20 of each 28-day cycle) with lenalidomide 
plus low-dose dexamethasone (40 mg on days 1, 8, 15, and 22 of each 28-day cycle). After four 
induction cycles, the patients could decide whether to proceed to ASCT or continue therapy until 
disease progression [23]. Although lenalidomide plus high-dose dexamethasone was associated 
with a higher response rate (partial response [PR] or better, 79% vs 68%; p = 0.008), OS was 
shorter (87% vs 96%; p = 0.0002) and there were higher rates of AEs (52% vs 35%; p = 0.0001) 
compared with lenalidomide plus low-dose dexamethasone. OS was consistently superior across all 
age groups, including in patients aged ≥75 years [24]. Due to these compelling findings, the trial 
was stopped and patients receiving high-dose dexamethasone were crossed over to the low-dose 
arm. Based on its safety and efficacy profile, the International Myeloma Working Group guidelines 
recommend lenalidomide plus low-dose dexamethasone as the standard of care [6]. 
3. Novel agents and the optimal duration of treatment in transplant-
ineligible patients 
Continuous therapy may be able to suppress MRD in patients with CR and to reduce tumor burden 
in those with PR. This concept was investigated in some early studies using alkylators, steroids, and 
interferon. Studies with alkylators (melphalan) [25] and/or steroids (e.g., dexamethasone, 
prednisone) 25, 26 and 27 showed that these agents produced a significantly prolonged PFS, but 
had no impact on OS. Studies with interferon are controversial, with some studies having shown 
both a prolonged response duration and improved survival 28, 29 and 30, whereas others have 
shown longer response durations but no prolonged survival 31, 32 and 33, and a few have shown no 
long-term benefit 34, 35 and 36. Furthermore, long-term use of these agents is associated with 
safety concerns, an increased risk of acute myeloid leukemia (AML) in patients treated with long-
term melphalan, potential adverse effects on bone metabolism with steroids such as prednisone, and 
high rates of dose reductions and treatment discontinuations with interferon–based therapy 29, 
31 and 33. Based on these safety concerns, these agents are considered unsuitable for continuous 
treatment. 
4. Novel agents as continuous therapy 
The ideal regimen for continuous therapy must be efficacious, well tolerated, and convenient. Novel 
agents such as thalidomide, lenalidomide, and bortezomib have demonstrated efficacy when used as 
induction regimens, and are likely to become the standard of care in this setting. The potential of 
these agents in continuous therapy has also been investigated, with promising results as discussed in 
greater detail below (Table 1) 18, 19, 37, 38, 39, 40, 41 and 42. 
 
Table 1. Randomized studies employing continuous therapy, including induction and 





Although most of the studies investigating thalidomide as consolidation/maintenance therapy have 
followed stem-cell transplantation 15, 43, 44, 45 and 46, a few have assessed the use of continuous 
thalidomide in transplantation-ineligible patients 18, 19, 40 and 47. However, most of these studies 
did not investigate the contribution of maintenance therapy to the clinical outcomes. 
A study by Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) compared MPT 
followed by thalidomide maintenance with MP alone without maintenance, in patients aged ≤65 
years and younger patients unable to undergo transplantation [47]. The addition of thalidomide, 
administered continuously at a dose of 100 mg/day until disease progression, significantly improved 
PFS (21.8 months vs 14.5 months for MP; p = 0.004) and response rates (at least PR, 68.9% vs 
47.6%, respectively; p = 0.001), but had no effect on OS (45 months vs 48 months, respectively; p = 
0.79) after a median follow-up of 38.4 months [38]. The median duration of thalidomide therapy 
was 9.6 months. Patients in the MPT arm had a statistically significantly higher incidence of grade 
3–4 thrombosis/embolic AEs (12% vs 2%), peripheral neuropathy (10% vs 1%), infection (8% vs 
0%), and gastrointestinal AEs (6% vs 1%) [47]. 
A subsequent study by the Dutch-Belgium Hemato-Oncology Cooperative Group (HOVON) group 
similarly compared MPT followed by thalidomide maintenance therapy (50 mg/d) with MP alone 
and no maintenance therapy in patients aged >65 years [18]. After a median follow-up of 39 
months, the primary endpoint of event-free survival was 13 months for patients treated with MPT 
compared with 9 months for patients treated with MP (p < 0.001). Median OS was 40 months for 
MPT compared with 31 months for MP (p = 0.05). The overall grade 3–4 AEs were more frequent 
in the MPT group, primarily peripheral neuropathy, leading to a higher rate of discontinuation due 
to AEs (38%), compared with 7% in the MP group. However, despite the higher incidence of AEs 
associated with MPT, this did not have an impact on the health-related quality of life, suggesting 
that MPT may be a better regimen from the patient's perspective [48]. The survival benefit observed 
with continuous thalidomide was not confirmed by a Norwegian phase III study, which found no 
significant difference in either PFS or OS with MPT compared with MP [19]. 
An Austrian-led phase III randomized study compared induction therapy with up to nine cycles of 
thalidomide plus dexamethasone (TD) versus MP in patients with NDMM not eligible for HDT or 
ASCT because of age (aged >65 years), presence of significant comorbidities, insufficient stem cell 
reserve, or patient choice [49]. In the second phase of this study, 128 patients who had achieved at 
least stable disease were randomized, to maintenance therapy with either interferon α-2b (IFN), or 
thalidomide (100 mg/day) daily plus IFN (T-IFN) until progression or an inability to tolerate 
treatment [39]. With a median follow-up of 35 months for the analysis of maintenance therapy, PFS 
was significantly longer in the T-IFN group compared with the IFN group (27.7 months vs 13.2 
months; p = 0.0068) [39]; however, OS remained similar (52.6 months vs 51.4 months, 
respectively; p = 0.81). Although hematologic toxicity was comparable in the two maintenance 
groups, patients on T-IFN had significantly more neuropathy, constipation, skin toxicity, and renal 
impairment. 
The MRC Myeloma IX study was the first study to determine the effect of thalidomide maintenance 
therapy on survival outcomes. The study randomized a total of 820 patients treated with either a 
high-dose therapy in an intensive pathway (younger/fitter patients) or a non-intensive induction 
regimen. Following induction, patients were further randomized to thalidomide maintenance (50 
mg/day escalating to 100 mg/day) or no maintenance [40]. After a median follow-up from the start 
of maintenance of 38 months, there was a significant improvement in PFS with thalidomide 
maintenance (23 months vs 15 months; HR =1.45; p < 0.001); with effective treatment at relapse, 
theoretically, this could translate into a survival benefit [40]. Interestingly, the results were 
dependent on the baseline interphase fluorescence in situ hybridization (FISH) cytogenetic profile. 
The improvement in PFS was observed in patients with a favorable FISH profile, defined as the 
absence of adverse cytogenetic abnormalities and including hyperdiploidy, t(6;14) and t(11;14), and 
there was a trend toward a late benefit of thalidomide maintenance in OS. In contrast, in patients 
with adverse FISH profiles, including the presence of t(4;14), t(14;16), t(14;20), 1q+ or 17p−, 
thalidomide maintenance was associated with similar PFS periods, but worse OS (p = 0.009). These 
data suggest that thalidomide maintenance therapy may select for drug-resistant tumor clones in 
patients with high-risk cytogenetics, a possibility that requires further study. Of note, Morgan et al. 
performed a meta-analysis of this and other phase III trials that evaluated the effect of thalidomide 
maintenance therapy [40]. The meta-analysis found that, although the studies differed significantly 
in design and patient population, they showed a significantly extended OS (p = 0.047). The 
composite survival curve resulting from the pooled analysis of these trials, including 2456 patients, 
demonstrated a significant late OS benefit (p < 0.001). These data highlight the need for long-term 
follow-up in maintenance studies to demonstrate the benefits of this therapy on OS [40]. 
The duration of maintenance therapy across trials, including trials of thalidomide maintenance 
therapy, was short (range, 7–13.5 months) 18, 19, 39, 40 and 41 with a high rate of discontinuations 
due to AEs (up to 52% [40]), suggesting that thalidomide may not be suitable for long-term 
maintenance therapy. Treatment-emergent peripheral neuropathy was the most common reason for 
not initiating or for stopping maintenance 18, 19 and 40. 
4.2. Bortezomib plus thalidomide or as monotherapy 
The GIMEMA-MM-03-05 phase III study compared induction with VMP plus thalidomide 
(VMPT) followed by continuous bortezomib (1.3 mg/m
2
) plus thalidomide (50 mg/d) (VT) as 
maintenance for 2 years or until progression or relapse, versus standard induction with VMP 
without maintenance therapy [41]. After a median follow-up period of 23.2 months, median PFS 
was not reached in the VMPT-VT group and was 27.3 months in the VMP group. The intensive 
treatment approach significantly reduced the risk of progression by 33% (HR = 0.67; p = 0.002). 
There was no difference in OS (p = 0.77), but the 3-year survival rates in both groups were 87–
88%. A landmark analysis aimed at investigating the effect of maintenance therapy on PFS revealed 
that VT maintenance reduced the risk of disease progression by 51% (HR = 0.49; p = 0.0003) [50]. 
However, this benefit was not seen in patients aged >75 years. Grade 3–4 AEs were more common 
among patients treated with VMPT-VT, and included hematologic (38% vs 28%) and cardiac 
complications (10% vs 5%), as well as thromboembolic events (5% vs 2%). During the VT 
maintenance treatment, 8% of patients experienced grade 3–4 AEs with few cases of newly 
occurring peripheral neuropathy (5%) and a low rate of maintenance discontinuation due to AEs, 
indicating that long-term maintenance treatment with VT is feasible. These results are supported by 
the findings of a phase III study of bortezomib-based regimens in elderly NDMM patients 
(GEM05MAS65) [51]. Patients were randomized to VMP or VT plus prednisone (VTP) induction 
therapy. Patients completing induction were subsequently randomized to bortezomib given in 3-
weekly cycles (1.3 mg/m
2
 on days 1, 4, 8, and 11) every 3 months, and either prednisone (50 mg 
every other day) (VP) or thalidomide (50 mg/day) (VT), for up to 3 years. Maintenance treatment 
with both VP and VT was associated with additional tumor reduction and an approximately 2-fold 
improvement in CR rate (42%) compared with that after induction (24%). The median PFS for all 
patients was 31 months (median follow-up 32 months), which compares favorably with the PFS 
achieved with the VMP regimen in the VISTA trial (24 months) [21]; however, the 3-year OS rates 
in these studies were comparable (70% vs 68% in VISTA) [22]. Longer follow-up is needed to 
confirm the impact of bortezomib-based treatment on OS. 
The phase IIIb UPFRONT study is a community-based open-label study that will evaluate the 
safety and efficacy of three bortezomib-based induction regimens (bortezomib plus either 
dexamethasone [VD], thalidomide and dexamethasone [VTD], or melphalan and prednisone 
[VMP]) followed by bortezomib maintenance [52]. Preliminary data show that all induction 
regimens have high efficacy, with ORRs of 68%, 78%, and 71% with the VD, VTD, and VMP 
regimens, respectively. Maintenance monotherapy was well tolerated after these induction 
regimens, and the ORRs following bortezomib maintenance were 71%, 79%, and 73% for the VD, 
VTD, and VMP induction regimens, respectively. A quality of life (QoL) analysis from the 
UPFRONT study showed a decrease in mean global health status at first with all regimens, followed 
by a trend to stabilizing/improving score during the maintenance phase [53]. Data on survival 
outcomes are awaited. 
4.3. Lenalidomide 
The efficacy and safety of lenalidomide in patients with MM was first established in two landmark 
clinical trials in patients with RRMM (MM-009 and MM-010) 54 and 55. The trial with Biaxin 
(clarithromycin), Revlimid (lenalidomide)/dexamethasone (BiRD) combination therapy in patients 
with treatment-naïve symptomatic MM suggested that continued therapy improved the depth of 
response [56]. A later retrospective pooled analysis of the two landmark trials [57] demonstrated the 
benefit of continued lenalidomide therapy: half the patients improved their type of response from a 
PR to a CR or VGPR with further treatment. The use of a lenalidomide maintenance regimen was 
investigated in a further prospective, randomized, phase III trial (MM-015) in which elderly 
NDMM patients received melphalan, prednisone, lenalidomide with lenalidomide maintenance 
(MPR-R), MPR followed by placebo maintenance (MPR), or MP plus placebo followed by placebo 
maintenance (MP) [37]. Lenalidomide (10 mg/day, 21 days of a 28-day cycle) was administered 
until progression. In the primary comparison, MPR-R reduced the risk of progression by 60% 
compared with MP (HR = 0.40; p < 0.001), with a median PFS of 31 months versus 13 months with 
MP. The incidence of grade 3–4 hematologic AEs was higher with MPR induction versus MP 
(neutropenia 96% vs 37%; thrombocytopenia 50% vs 16%; and anemia 29% vs 15%). The effect of 
maintenance treatment on PFS was examined in a landmark analysis comparing the MPR-R and 
MPR arms for patients who completed induction. This analysis demonstrated that maintenance 
lenalidomide resulted in a 66% reduced risk of progression compared with no maintenance (HR = 
0.34; p < 0.001). Lenalidomide maintenance was well tolerated with no evidence of cumulative 
toxicity and low rates of newly occurring AEs; grade 3–4 hematologic AEs included neutropenia 
7%, thrombocytopenia 6%, and anemia 4% [37]. 
An increase in the incidence of second primary malignancies (SPMs) was observed in the study of 
lenalidomide maintenance treatment (MM-015) The 3-year risk of an invasive SPM was 7% with 
MPR-R and 3% with MP [37]. Twelve cases of SPM were reported in the MPR-R arm, nine in the 
MPR arm and four in the MP arm. These included seven hematologic SPMs in the MPR-R arm 
(four AML, one acute lymphoblastic leukemia [ALL], one myelodysplastic syndrome [MDS], one 
chronic myelomonocytic leukemia [CMML]), five in the MPR arm (two AML, three MDS) and one 
in the MP arm (MDS). There were also five invasive solid tumors in the MPR-R arm, four in the 
MPR arm and three in the MP arm. No B-cell malignancies were reported. Two other analyses of 
SPM rates in NDMM patients following lenalidomide treatment have recently been published. An 
analysis of pooled data from 2459 NDMM patients (median age 69 years) treated with lenalidomide 
in nine clinical trials carried out by the European Myeloma Network [58] identified a low SPM 
incidence rate of 0.72 per 100 patient years which included eight hematologic and 22 solid cancers. 
In addition, analysis of a cohort of patients treated with lenalidomide as first-line therapy in 
combination with clarithromycin and dexamethasone (BiRD) regimen until disease progression [59] 
did not identify an increased incidence of SPM and no hematologic SPMs were observed after six 
years of follow-up. In conclusion, physicians should bear in mind the risk of SPM when considering 
continuous lenalidomide treatment and all patients should be evaluated for SPMs using standard 
cancer screening methods before, and regularly during, lenalidomide treatment. However, the risk 
of death due to progression of MM remains far higher than the risk of developing a secondary 
cancer [60] and in the context of the significant gains in PFS associated with lenalidomide 
maintenance treatment, the risk: benefit profile of continuous lenalidomide treatment remains 
positive. 
4.4. Other induction/consolidation/maintenance regimens 
Other induction/consolidation/maintenance approaches are being tested in clinical trials. For 
example, a recent single-arm phase II study evaluated induction therapy with bortezomib, 
dexamethasone, and pegylated liposomal doxorubicin (PAD), followed by reduced intensity ASCT 
(tandem melphalan 100 mg/m
2
 [MEL100] with stem-cell support), and PAD followed by 
consolidation therapy with lenalidomide (25 mg/day for 21 days of each 28-day cycle) plus 
prednisone (50 mg every other day) (LP), followed by maintenance therapy with lenalidomide (10 
mg/day for 21 days of each 28-day cycle) (LP-Len) until relapse. The study included 102 NDMM 
patients with a median age of 67 years, 26% of whom were aged >70 years [61]. The 
immunofixation-negative CR rate increased from 13% after PAD induction, to 38% after MEL100, 
and 66% after LP-Len consolidation-maintenance. After a median follow-up of 21 months, the 2-
year PFS rate was 69% and the 2-year OS was 86%. Lenalidomide consolidation was generally well 
tolerated with no cumulative hematologic AEs. This interesting sequential approach, evaluating 
lenalidomide as both consolidation and maintenance, requires testing in a randomized phase III 
setting. A second, two-stage, phase II trial, investigated the safety and efficacy of lenalidomide plus 
prednisone (RP) induction therapy followed by MPR consolidation, and lenalidomide maintenance 
in unfit elderly patients aged >65 years. Response rates at induction were 73% PR or better, and this 
increased following MPR consolidation (78% achieved PR or better). This treatment regimen was 
found to have a manageable safety profile with reduced risks of anemia, thrombocytopenia, and 
non-hematologic events during MPR consolidation in the unfit elderly population [62]. 
5. Ongoing continuous therapy trials with novel agents 
There are several different continuous therapy regimens being tested in ongoing randomized phase 
III studies in NDMM patients ineligible for transplantation (Fig. 1). Five of these studies 
investigated lenalidomide-based continuous therapy regimens, and all treated patients until disease 
progression. One study evaluated lenalidomide alone, one evaluated lenalidomide plus prednisone, 
and three studies evaluated lenalidomide plus dexamethasone. There are also four studies 
investigating bortezomib-based continuous therapy regimens. Of interest, two of the bortezomib 
studies treated patients until disease progression (bortezomib alone and bortezomib plus 
thalidomide), whereas the others defined “maintenance” as four cycles (cycles 9–13). 
 Fig. 1. Schematic of ongoing studies investigating maintenance regimens. BAM, bortezomib, 
ascorbic acid, and melphalan; CPR, cyclophosphamide, prednisone, and lenalidomide; Dd-R, low 
frequency dexamethasone and lenalidomide; MPR, melphalan, prednisone, and lenalidomide; MPT, 
melphalan, prednisone, and thalidomide; RD, lenalidomide plus dexamethasone; RLD, 
lenalidomide plus low-dose dexamethasone; RLDV, lenalidomide, low-dose dexamethasone, and 
bortezomib; VD, bortezomib and dexamethasone; VDC, bortezomib, dexamethasone, and 
cyclophosphamide; VDC-mod, modified dosing of VDC; VDCR, bortezomib, dexamethasone, 
cyclophosphamide, and lenalidomide; VDR, bortezomib, dexamethasone, and lenalidomide; VMP, 
bortezomib, melphalan, and prednisone; VMPT, VMP plus thalidomide; VTD, bortezomib, 
thalidomide. and dexamethasone. 
 
6. Challenges in the interpretation of studies investigating continuous 
therapy 
Current evidence from clinical studies of novel agents suggests that although continuous therapy 
may be associated with a PFS benefit, this benefit does not always translate into an improvement in 
OS. Furthermore, the studies of continuous therapy published to date have had widely differing 
study designs and patient populations making comparison between studies difficult. Different 
induction regimens were used 25, 26, 29 and 31, the length of induction and the duration of follow-
up varied, there was heterogeneity in patient characteristics across studies (for example, the 
cytogenetic profiles of patients) 5, 40 and 63, and type of salvage therapy used at relapse 26, 
31 and 41 varied substantially. In addition, interpretation of the results from the maintenance phases 
of these studies could be confounded by closer observation of patients in the control (no 
maintenance) arm. 
7. Future perspectives 
For transplant-ineligible patients, continuous long-term therapy with novel agents prolongs the TTP 
and suggests the need for a change in the treatment paradigm. In accordance with this new 
perspective, treatment for transplant-ineligible MM patients should include: (a) achievement of 
high-quality responses with effective induction combination regimens including novel agents; and 
(b) sustainment of the response with maintenance therapy. Although an OS benefit of maintenance 
therapies is not yet apparent, such a benefit may emerge with longer follow-up periods [64]. Several 
unanswered questions should be addressed by future research: Should maintenance therapy be 
administered to all elderly patients with NDMM? Are there any clinical characteristics, such as 
cytogenetic profile, which would help predict which patients would benefit most from continuous 
therapy? What type of dosing regimen/schedule is needed to provide optimal disease control while 
balancing safety and tolerability, considering that the patients are usually elderly and frail? Does 
continuous therapy result in the development of more aggressive/resistant disease, and if so, in 
which patients? Should maintenance therapy be given for a limited period (for example, 2–3 years), 
or continuously until relapse or disease progression? Are there biological markers that can indicate 
when treatment can be stopped without risk of relapse? What is the optimal subsequent treatment 
approach in patients relapsing on continuous therapy? More well-designed, comparative studies 
with longer follow-up periods are needed to answer these questions. 
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